As PTC prepares to release its Q4 financial results, investors are weighing its strong historical performance against a turbulent market for vertical software stocks. Here’s the breakdown.
Arcellx shares have delivered stellar multi-year gains, prompting investors to question if the rally still has room to run. A deep dive into valuation metrics reveals a complex picture, with discounted cash flow models pointing to significant upside while price-to-book ratios suggest a more cautious stance.
Eli Lilly's $3.5 billion investment in a new Pennsylvania facility for injectable weight-loss drugs, including retatrutide, spotlights its aggressive expansion in the obesity market. This strategic move, coupled with strong analyst sentiment and upcoming earnings, intensifies focus on the company's growth trajectory and premium valuation.
Amgen has terminated its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab, handing full development rights back to the Japanese partner. The strategic shift comes as Amgen's stock trades above most fair value estimates, raising questions about its current valuation amid pipeline recalibration.
Shares of Coastal Financial (CCB) have tumbled over 13% in the past month, sparking debate among investors. While a proprietary valuation model suggests the stock is deeply undervalued, its premium P/E ratio tells a conflicting story. We examine the numbers and the broader context for regional banks.
Energy Recovery (ERII) sees its price target raised to $23 by analysts, reflecting increased confidence in the adoption timeline for its CO2 refrigeration technology, despite stable core valuation metrics. The shift underscores a nuanced market narrative focused on execution rather than a fundamental change in long-term prospects.
Palantir Technologies' stock surged after hours as the data analytics firm reported record quarterly results, fueled by its AI platform. CEO Alex Karp hailed an 'iconic' performance while warning that the company's dominance creates societal and political tensions.
Elon Musk announces the merger of SpaceX and xAI, outlining an ambitious plan to construct solar-powered data centers in space, which he claims will become the most cost-effective source of AI computing power within years.
As Mueller Water Products prepares to release its fourth-quarter results, investors are watching for signs of sustained growth in the critical water infrastructure sector. The company has a strong track record of exceeding revenue expectations.
As Fortive prepares to release its fourth-quarter results, investors are weighing slowing revenue growth projections against a backdrop of robust peer performance and cautious analyst sentiment. The industrial technology firm's ability to meet or exceed forecasts could signal its resilience in a fluctuating market.
All eyes are on Stanley Black & Decker (SWK) as it prepares to release its quarterly earnings. Investors are looking for signs of a sustained turnaround amid a mixed industrial machinery landscape.
Alphabet's self-driving unit Waymo has raised $16 billion in a landmark funding round, valuing the company at $126 billion. The capital injection, backed by major investors including Alphabet and Dragoneer, is set to fuel an aggressive international expansion of its autonomous ride-hailing service.
As Kennametal (KMT) prepares to release its quarterly results, investors are weighing strong recent performance against a history of revenue misses. The report comes amid mixed signals from the industrial machinery sector.
The Timken Company (NYSE: TKR) is scheduled to release its fourth-quarter financial results before the market opens on Wednesday. Investors will be watching to see if the bearings and power transmission specialist can continue its track record of surpassing Wall Street's forecasts amidst a mixed landscape for industrial machinery firms.
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
As TTM Technologies prepares to release its quarterly results, analysts anticipate sustained revenue growth and robust performance in the competitive PCB manufacturing sector.
Marius Borg Høiby, the son of Norway's Crown Princess Mette-Marit, is set to stand trial on Tuesday, facing a litany of charges including rape, domestic violence, and drug possession. The case marks a profound crisis for the modern Norwegian monarchy, unfolding against a backdrop of other royal controversies and health concerns.
French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.
Specialist asset manager Cohen & Steers (NYSE: CNS) is attracting bullish attention as its focus on real assets aligns with a shifting monetary policy landscape. After a prolonged period of outflows, the firm is seeing renewed investor interest.
